Development of novel HDAC/PI3K dual inhibitors
Project/Area Number |
25830110
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor therapeutics
|
Research Institution | Tohoku University |
Principal Investigator |
SAIJO KEN 東北大学, 大学病院, 助教 (70636729)
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 分子標的薬 / 創薬 / HDAC阻害剤 / PI3K阻害剤 / がん分子標的治療薬剤 / HDAC阻害 / PI3K阻害 / 非臨床試験 |
Outline of Final Research Achievements |
Both HDAC and PI3K are considered to be promising targets for cancer therapy. A combination of an HDAC inhibitor and a PI3K inhibitor potentiates the cytotoxic effect in a synergistic manner. Therefore, development of an HDAC/PI3K dual inhibitor will provide an attractive novel drug. The depsipeptide analogs have been identified as HDAC/PI3K dual inhibitors. Moreover, using structure based optimization, FK-A11 has been identified as the most potent analog. FK-A11 showed anti-tumor effects in vivo mouse model using human prostate cancer cells.
|
Report
(3 results)
Research Products
(7 results)